Published online February 25, 2008
PEDIATRICS Vol. 121 No. 3 March 2008, pp. e626-e630 (doi:10.1542/peds.2007-1218)

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Services E-mail this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to My File Cabinet Download to citation manager Request Permissions Citing Articles Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Manlhiot, C. Articles by Feldman, B. M. Search for Related Content PubMed PubMed Citation Articles by Manlhiot, C. Articles by Feldman, B. M. Related Collections Allergy & Dermatology Social Bookmarking                         What's this?

ARTICLE

Safety of Intravenous Immunoglobulin in the Treatment of Juvenile Dermatomyositis: Adverse Reactions Are Associated With Immunoglobulin A Content

Cedric Manlhiot, BSc^a, Pascal N. Tyrrell, MSc^a, Lisa Liang, BSc^a, Adelle R. Atkinson, MD, FRCPC^b, Wendy Lau, MBBS, FRCP(C)^c and Brian M. Feldman, MD, MSc, FRCP(C)^a,d,e

Divisions of ^a Rheumatology
^b Immunology/Allergy, Department of Pediatrics
^c Division of Transfusion Medicine, Department of Pediatric Laboratory Medicine
^d Department of Health Policy Management and Evaluation
^e Department of Public Health Sciences, University of Toronto, The Hospital for Sick Children, Toronto, Ontario, Canada

OBJECTIVE. Anecdotal reports have suggested differences in children's tolerance to different intravenous immunoglobulin products; however, there has been little research on this issue. We sought to determine whether different intravenous immunoglobulin products used in the treatment of juvenile dermatomyositis are equally well tolerated by patients and, if not, whether differences in tolerance are linked to immunoglobulin A content.

PATIENTS AND METHODS. The intravenous immunoglobulin infusion history (product given and history of adverse events) of patients who were attending the juvenile dermatomyositis clinic at the Hospital for Sick Children from 1986 to 2005 was reviewed. Products with an immunoglobulin A content of >15 µg/mL were classified as "high immunoglobulin A." Data were analyzed by using logistic regression models adjusted for repeated measures.

RESULTS. Thirty-eight patients with juvenile dermatomyositis received 1056 infusions at the Hospital for Sick Children. Adverse events were reported on 92 occasions (9%), affecting 25 patients (66%), a frequency that is higher than that usually reported in adult patients (<1%–5%). Adverse events were reported more often with products that contained high immunoglobulin A (15.0% vs 8.0%). These were accounted for specifically by fever (8.0% vs 1.0%), lethargy or malaise (2.0% vs 0.1%), and nausea or vomiting (5.0% vs 1.0%). Of the possible pharmacologic predictors, including dose, immunoglobulin G concentration, immunoglobulin A level, pH, glycine content, sugar content, sodium content, and osmolality, only immunoglobulin A level was significantly associated with adverse events.

CONCLUSIONS.Intravenous immunoglobulin was found to be safe and well tolerated by most children with juvenile dermatomyositis. However, in contrast to adult studies, we found that significant differences existed in tolerance to different intravenous immunoglobulin products, most likely because of immunoglobulin A concentration. This study confirms anecdotal reports that a high level of immunoglobulin A in intravenous immunoglobulin is less well tolerated by children and provides evidence that product choice is important in pediatrics.

---

Key Words: immunoglobulin (intravenous) • IgA • drug safety • dermatomyositis (juvenile)

Abbreviations: IVIg—intravenous immunoglobulin • JDM—juvenile dermatomyositis • IgA—immunoglobulin A

---

Accepted Aug 16, 2007.

CiteULike    Connotea    Del.icio.us    Digg    Facebook    Reddit    Technorati    Twitter    What's this?